Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Q2 net loss widens to $111.5 million; CFO Jennifer Fox to step down

Mixed Impact 4 of 5 earnings Written later

Zenas BioPharma reported a second-quarter 2026 net loss of $111.5 million, up from $52.2 million a year earlier, as research and development and acquired in-process research costs rose. The company also said CFO Jennifer Fox will move to a strategic advisor role to the Board Chair on September 30, 2026, and that Christy Oliger was appointed to the board effective September 1, 2026.

Key points

  • Q2 2026 revenue was $1.0 million, tied to a development milestone, versus none in Q2 2025.
  • R&D expenses rose to $62.9 million from $43.0 million, and acquired in-process R&D expenses were $30.0 million.
  • Cash, cash equivalents and investments were $673.9 million as of June 30, 2026.
  • Joe Farmer, President and COO, will serve as principal financial and accounting officer until a CFO is appointed.

The filing

CompanyZenas BioPharma, Inc. (ZBIO)
Form8-K, current report
Filed with the SECAug 13, 2026, 7:05 AM ET
Accession number0001104659-26-095437

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.